- call +1-201-465-4211
- email sales@mrinsights.biz
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation.
Scope of the Report:
This report focuses on the Opioid-Induced Constipation in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite.
The worldwide market for Opioid-Induced Constipation is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
AstraZeneca
Takeda Pharmaceutical
Valeant Pharmaceuticals International
Abbott
Bayer
Boehringer Ingelheim
C.B. Fleet
Cosmo Pharmaceuticals
Daewoong
Daiichi Sankyo
GlaxoSmithKline
Ironwood Pharmaceuticals
Johnson & Johnson
Merck
Mundipharma
Nektar Therapeutics
Pfizer
Progenics Pharmaceuticals
Shionogi
SLA Pharma
Sucampo
Synergy Pharmaceuticals
Theravance
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Solid
Liquid
Market Segment by Applications, can be divided into
Drugstore
Hospital
Others
There are 15 Chapters to deeply display the global Opioid-Induced Constipation market.
Chapter 1, to describe Opioid-Induced Constipation Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Opioid-Induced Constipation, with sales, revenue, and price of Opioid-Induced Constipation, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Opioid-Induced Constipation, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Opioid-Induced Constipation market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Opioid-Induced Constipation sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Opioid-Induced Constipation Introduction
1.2 Market Analysis by Type
1.2.1 Solid
1.2.2 Liquid
1.3 Market Analysis by Applications
1.3.1 Drugstore
1.3.2 Hospital
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 Business Overview
2.1.2 Opioid-Induced Constipation Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Takeda Pharmaceutical
2.2.1 Business Overview
2.2.2 Opioid-Induced Constipation Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Takeda Pharmaceutical Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Valeant Pharmaceuticals International
2.3.1 Business Overview
2.3.2 Opioid-Induced Constipation Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Valeant Pharmaceuticals International Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Abbott
2.4.1 Business Overview
2.4.2 Opioid-Induced Constipation Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Abbott Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bayer
2.5.1 Business Overview
2.5.2 Opioid-Induced Constipation Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bayer Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Boehringer Ingelheim
2.6.1 Business Overview
2.6.2 Opioid-Induced Constipation Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Boehringer Ingelheim Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 C.B. Fleet
2.7.1 Business Overview
2.7.2 Opioid-Induced Constipation Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 C.B. Fleet Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Cosmo Pharmaceuticals
2.8.1 Business Overview
2.8.2 Opioid-Induced Constipation Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Cosmo Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Daewoong
2.9.1 Business Overview
2.9.2 Opioid-Induced Constipation Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Daewoong Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Daiichi Sankyo
2.10.1 Business Overview
2.10.2 Opioid-Induced Constipation Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 GlaxoSmithKline
2.11.1 Business Overview
2.11.2 Opioid-Induced Constipation Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 GlaxoSmithKline Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Ironwood Pharmaceuticals
2.12.1 Business Overview
2.12.2 Opioid-Induced Constipation Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Ironwood Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Johnson & Johnson
2.13.1 Business Overview
2.13.2 Opioid-Induced Constipation Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Johnson & Johnson Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Merck
2.14.1 Business Overview
2.14.2 Opioid-Induced Constipation Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Merck Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Mundipharma
2.15.1 Business Overview
2.15.2 Opioid-Induced Constipation Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Mundipharma Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 Nektar Therapeutics
2.16.1 Business Overview
2.16.2 Opioid-Induced Constipation Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.17 Pfizer
2.17.1 Business Overview
2.17.2 Opioid-Induced Constipation Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Pfizer Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.18 Progenics Pharmaceuticals
2.18.1 Business Overview
2.18.2 Opioid-Induced Constipation Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.19 Shionogi
2.19.1 Business Overview
2.19.2 Opioid-Induced Constipation Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Shionogi Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.20 SLA Pharma
2.20.1 Business Overview
2.20.2 Opioid-Induced Constipation Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 SLA Pharma Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.21 Sucampo
2.21.1 Business Overview
2.2.2 Opioid-Induced Constipation Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Sucampo Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.22 Synergy Pharmaceuticals
2.22.1 Business Overview
2.22.2 Opioid-Induced Constipation Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Synergy Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.23 Theravance
2.23.1 Business Overview
2.23.2 Opioid-Induced Constipation Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Theravance Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Opioid-Induced Constipation Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Opioid-Induced Constipation Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Opioid-Induced Constipation Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Opioid-Induced Constipation Manufacturer Market Share in 2017
3.3.2 Top 6 Opioid-Induced Constipation Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Opioid-Induced Constipation Market Analysis by Regions
4.1 Global Opioid-Induced Constipation Sales, Revenue and Market Share by Regions
4.1.1 Global Opioid-Induced Constipation Sales and Market Share by Regions (2013-2018)
4.1.2 Global Opioid-Induced Constipation Revenue and Market Share by Regions (2013-2018)
4.2 North America Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
4.3 Europe Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
4.5 South America Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
5 North America Opioid-Induced Constipation by Countries
5.1 North America Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
5.1.1 North America Opioid-Induced Constipation Sales and Market Share by Countries (2013-2018)
5.1.2 North America Opioid-Induced Constipation Revenue and Market Share by Countries (2013-2018)
5.2 United States Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
5.3 Canada Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
5.4 Mexico Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
6 Europe Opioid-Induced Constipation by Countries
6.1 Europe Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
6.1.1 Europe Opioid-Induced Constipation Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Opioid-Induced Constipation Revenue and Market Share by Countries (2013-2018)
6.2 Germany Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
6.3 UK Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
6.4 France Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
6.5 Russia Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
6.6 Italy Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
7 Asia-Pacific Opioid-Induced Constipation by Countries
7.1 Asia-Pacific Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Opioid-Induced Constipation Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Opioid-Induced Constipation Revenue and Market Share by Countries (2013-2018)
7.2 China Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
7.3 Japan Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
7.4 Korea Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
7.5 India Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
8 South America Opioid-Induced Constipation by Countries
8.1 South America Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
8.1.1 South America Opioid-Induced Constipation Sales and Market Share by Countries (2013-2018)
8.1.2 South America Opioid-Induced Constipation Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
8.3 Argentina Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
8.4 Colombia Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
9 Middle East and Africa Opioid-Induced Constipation by Countries
9.1 Middle East and Africa Opioid-Induced Constipation Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Opioid-Induced Constipation Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Opioid-Induced Constipation Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
9.3 UAE Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
9.4 Egypt Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
9.5 Nigeria Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
9.6 South Africa Opioid-Induced Constipation Sales and Growth Rate (2013-2018)
10 Global Opioid-Induced Constipation Market Segment by Type
10.1 Global Opioid-Induced Constipation Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Opioid-Induced Constipation Sales and Market Share by Type (2013-2018)
10.1.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2013-2018)
10.2 Solid Sales Growth and Price
10.2.1 Global Solid Sales Growth (2013-2018)
10.2.2 Global Solid Price (2013-2018)
10.3 Liquid Sales Growth and Price
10.3.1 Global Liquid Sales Growth (2013-2018)
10.3.2 Global Liquid Price (2013-2018)
11 Global Opioid-Induced Constipation Market Segment by Application
11.1 Global Opioid-Induced Constipation Sales Market Share by Application (2013-2018)
11.2 Drugstore Sales Growth (2013-2018)
11.3 Hospital Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Opioid-Induced Constipation Market Forecast (2018-2023)
12.1 Global Opioid-Induced Constipation Sales, Revenue and Growth Rate (2018-2023)
12.2 Opioid-Induced Constipation Market Forecast by Regions (2018-2023)
12.2.1 North America Opioid-Induced Constipation Market Forecast (2018-2023)
12.2.2 Europe Opioid-Induced Constipation Market Forecast (2018-2023)
12.2.3 Asia-Pacific Opioid-Induced Constipation Market Forecast (2018-2023)
12.2.4 South America Opioid-Induced Constipation Market Forecast (2018-2023)
12.2.5 Middle East and Africa Opioid-Induced Constipation Market Forecast (2018-2023)
12.3 Opioid-Induced Constipation Market Forecast by Type (2018-2023)
12.3.1 Global Opioid-Induced Constipation Sales Forecast by Type (2018-2023)
12.3.2 Global Opioid-Induced Constipation Market Share Forecast by Type (2018-2023)
12.4 Opioid-Induced Constipation Market Forecast by Application (2018-2023)
12.4.1 Global Opioid-Induced Constipation Sales Forecast by Application (2018-2023)
12.4.2 Global Opioid-Induced Constipation Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Opioid-Induced Constipation Picture
Table Product Specifications of Opioid-Induced Constipation
Figure Global Sales Market Share of Opioid-Induced Constipation by Ty
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
